About this Course
The School of Pharmacy Henry A. Palmer CE Finale, named for beloved professor and mentor, Dr. Henry A. Palmer, is a continuing education program offered at the end of each calendar year. Held during December, the program helps pharmacists and perhpas pharmacy technicians fulfill their last minute CE requirements. The program is typically not a single theme, but an ala carte program offering a variety of presentations covering contemporary issues in pharmacy practice/therapeutics. These are recordings of the encore webinars presented the week following the live event. This is NOT considered live CE, but is enduring CE.
When you are ready to submit quiz answers, go to the Blue "Take Test/Evaluation" Button.
Target Audience
Pharmacists and Pharmacy Technicians interested in Clinical Practice.
Pharmacist & Pharmacy Techncian Learning Objectives
At the end of this knowledge-based continuing education activity, the learner will be able to:
· Describe the current drug overdose crisis. |
· Elaborate how COVID-19 has affected substance use disorder |
· Discuss regulatory and public health activities that could mitigate the problem. |
Release Date
Released: 12/11/2020
Expires: 12/11/2023
Course Fee
$15
ACPE UAN Codes
0009-0000-20-067-H03-P/T
Accreditation Hours
1.0 hours of CE
Accreditation Statement
The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of credit for the online activity ADD ACPE UAN 0009-0000-20-067-H03-P/T will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.
Grant Funding
There is no grant funding for this activity.
Requirements for Successful Completion
To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.
Type in your NABP ID, DOB and the session code for the activity. You were sent the session code in your confirmation email and it is listed above.
Faculty
Gerald Gianutsos, PhD, JD
Emeritus Associate Professor of Pharmacology
University of Connecticut School of Pharmacy
Storrs, CT
Faculty Disclosure
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
Dr. Gianutsos has no relationship with an ineligible company and therefore has nothing to disclose.
Disclaimer
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Program Content
Program Handouts
Post Test Evaluation
View Questions for Pharmacist & Techincian Law: When Crisis Meets a Crisis
- Which drug(s) which have been most responsible for overdose deaths in the U.S.?
- Heroin
- Synthetic opioids like fentanyl
- Prescription opioids
- What trend do experts expect to see with regard to the number of drug overdoses during the pandemic year 2020?
- Increase relative to 2019
- Decrease relative to 2019
- Remain about the same as 2019
- Which of the following factors is NOT associated with increased susceptibility to a fatal drug overdose in patients with COVID-19?
- Compromised lung function from COVID-19 and chronic respiratory disease
- Compromised cardiovascular function associated with COVID-19
- Anti-viral drugs used to treat COVID-19 patients
- What demographic group is disproportionately most likely to start or increase substance use to cope with pandemic-related stress or emotions?
- Patients 65 and older
- Men aged 18-24
- Unpaid caregivers caring for an adult with COVID-19
- Which drug has accounted for the largest increase in drug overdose deaths following the emergence of the pandemic?
- Fentanyl
- Cocaine
- Prescription opioids
- Social-isolation limitations and lockdowns complicated treatment for people who struggle with addiction disorders and for the organizations that provide services during the pandemic. Which of the following factors contributed?
- Overall, stress decreased since people could work from home
- Addiction support groups were exempt from stay-at-home orders
- Border and other restrictions lead to drug shortage and price hikes
- What did the American Medical Association (AMA) recommend should happen during the pandemic?
- Implement stricter limits on prescribing of opioids in all states
- Designate buprenorphine and methadone as “essential services”
- Increase the use of drug testing for prison inmates on parole
- Kansas has implemented “work-at-home” regulations during the pandemic. Which of the following is NOT part of their regulations?
- Technicians can enter prescriptions remotely at any time
- A pharmacist may supervise a technician who is working remotely but must be physically present at the pharmacy when doing so
- An intern may work remotely but any time spent remotely working would not count towards the hours required for licensure
- Which of the following is a change in the DEA regulations in response to the pandemic?
- The requirement for a follow-up original prescription for an oral emergency C-II prescription has been extended from 7 days to 10 days.
- The follow-up original prescription for an oral emergency C-II prescription must be electronically submitted.
- Authorized practitioners may prescribe buprenorphine after a phone interview with patients who have addiction problems.
- What is the permitted technician to pharmacist ratio during the pandemic in Indiana?
- 3 to 1
- 6 to 1
- 8 to 1